Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Pharmacology Study of CS-3150: Absolute Bioavailability and Food Effect in Healthy Japanese Subjects
jRCT2080223397Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esaxerenone in hypertension (HTN) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Absolute bioavailability of esaxerenone 5 mg oral dose (fasting), Absolute bioavailability of esaxerenone 5 mg oral dose (postprandial) and 1 more. Started Dec 2016; status: completed.
02
Drugs
esaxerenone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2080223397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223397.